Transcatheter mitral valve implantation (TMVI) is the optimal type of surgical treatment for elderly patients with mitral stenosis with a high risk of mortality in traditional surgical correction of defects.

Mitral valve prosthesis is the main method of treating mitral stenosis – a partial narrowing of the mitral valve lumen, which provokes difficulty in blood flow from the left atrium of the heart to the left ventricle. Mitral valve insufficiency may also be an indication for implantation.

Endovascular aortic valve prosthesis is used in cases where standard “open” surgery is associated with high surgical risks. This operation is indicated for patients with mitral regurgitation who suffer from severe comorbidities: vascular lesions, chronic diseases of the lungs, liver, endocrine pathology, oncology.

In this case, the replacement of the aortic valve is performed without large surgical incisions through the puncture of the femoral artery under X-ray control without artificial circulation and general anesthesia. One of the advantages of this technology is the reduction of side effects of sternotomy (dissection of the sternum): blood loss, the intensity of pain during the patient’s stay in the hospital, the risk of infection associated with the postoperative suture. The use of endovascular technologies significantly reduces the rehabilitation period of patients.